Regulation - Pricing, North America

Filter

Current filters:

PricingNorth America

Popular Filters

US FDA approval for Gilead's hepatitis C drug Sovaldi

US FDA approval for Gilead's hepatitis C drug Sovaldi

08-12-2013

US antiviral biotech specialist Gilead Sciences says that the Food and Drug Administration has approved…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPricingRegulationsofosbuvirSovaldi

Unnecessary drug regulations hiking Rx prices in USA: NCPA Study

08-03-2013

As drug coverage increases as a result of expanded health insurance and Medicaid coverage under the USA's…

BiotechnologyNorth AmericaPharmaceuticalPricingRegulation

AHF calls for Gilead's Quad HIV pill to be put on "prior authorization" status

19-08-2012

In what may be an unprecedented move on drug pricing and access, advocates from the AIDS Healthcare Foundation…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalPricingQuadRegulation

US patients get faster access to more cancer drugs than Europeans, says Tufts

11-07-2012

Cancer patients in the USA get faster access to more oncology drugs to treat their disease than patients…

BiotechnologyEuropeHealthcareNorth AmericaOncologyPharmaceuticalPricingRegulation

Gilead files elvitegravir and cobicistat with FDA; AHF plea on Quad pricing

29-06-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), world's largest maker of HIV drugs, has submitted a New…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaPricingQuadRegulation

High expectations for new US biosimilars following FDA guidance documents

10-05-2012

In light of the upcoming FDA guidance for biosimilar approval, Novation, health care supply chain expertise…

BiotechnologyGenericsNorth AmericaPricingRegulation

Bayer's Xarelto reimbursement backed in Canada; EMA concludes Yvidually arbitration

24-04-2012

The Canadian Agency for Drugs and Technologies in Health (CADTH) through the Common Drug Review (CDR),…

BayerCardio-vascularEuropeNorth AmericaPharmaceuticalPricingRegulationReproductiveXareltoYvidually

Affymax and Takeda get special Medicare code for Omontys

16-04-2012

USA-based Affymax (Nasdaq: AFFY) and the US subsidiary of Japanese drug major Takeda Pharmaceuticals…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontysOncologypeginesatidePharmaceuticalPricingRegulationTakeda Pharmaceuticals

Canadian patients wait two and a half years for new drug access

09-04-2012

As a result of government bureaucracies to approve new prescription drugs for public use, Canadians are…

North AmericaPharmaceuticalPoliticsPricingRegulation

Merck gains expanded Isentress indication; lowers price of drug for ADAps

23-12-2011

In two pieces of HIV/AIDS-related news for US drugs giant Merck & Co (NYSE: MRK), the company’s…

Anti-viralsIsentressMerck & CoNorth AmericaPharmaceuticalPricingRegulation

Back to top